Faes Farma SA (FAE) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 14.48%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 17.27

Poor long term growth as Net Sales has grown by an annual rate of 0.39% over the last 5 years

With ROE of 4.35%, it has a Expensive valuation with a 1.89 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 1,376 Million (Small Cap)

P/E

43.00

Industry P/E

Dividend Yield

418.57%

Debt Equity

-0.02

Return on Equity

4.35%

Price to Book

1.89

Revenue and Profits:

Net Sales:

57 Million

(Quarterly Results - Mar 2016)

Net Profit:

8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

32.92%

6 Months

19.23%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Faes Farma SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.39%

EBIT Growth (5y)

28.40%

EBIT to Interest (avg)

17.27

Debt to EBITDA (avg)

0.53

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

0.34

Tax Ratio

21.53%

Dividend Payout Ratio

40.52%

Pledged Shares

Institutional Holding

ROCE (avg)

14.09%

ROE (avg)

14.48%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.89

EV to EBIT

43.81

EV to EBITDA

34.67

EV to Capital Employed

1.90

EV to Sales

6.48

PEG Ratio

2.61

Dividend Yield

418.57%

ROCE (Latest)

4.34%

ROE (Latest)

4.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'16 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2016 is 10.92% vs 5.12% in Mar 2015",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2016 is 19.12% vs 19.30% in Mar 2015",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'16",
        "Mar'15",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56.90",
          "val2": "51.30",
          "chgp": "10.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.80",
          "val2": "11.10",
          "chgp": "15.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.10",
          "val2": "6.80",
          "chgp": "19.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "193.30%",
          "val2": "175.40%",
          "chgp": "1.79%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.40% vs 2.83% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.16% vs 2.57% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "493.60",
          "val2": "451.20",
          "chgp": "9.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "112.70",
          "val2": "100.60",
          "chgp": "12.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "111.10",
          "val2": "91.70",
          "chgp": "21.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "187.20%",
          "val2": "180.00%",
          "chgp": "0.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'16 - YoY

Mar'16

Mar'15

Change(%)

Net Sales

56.90

51.30

10.92%

Operating Profit (PBDIT) excl Other Income

12.80

11.10

15.32%

Interest

0.30

0.00

Exceptional Items

0.00

Consolidate Net Profit

8.10

6.80

19.12%

Operating Profit Margin (Excl OI)

193.30%

175.40%

1.79%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2016 is 10.92% vs 5.12% in Mar 2015

Consolidated Net Profit

YoY Growth in quarter ended Mar 2016 is 19.12% vs 19.30% in Mar 2015

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

493.60

451.20

9.40%

Operating Profit (PBDIT) excl Other Income

112.70

100.60

12.03%

Interest

0.70

Exceptional Items

0.00

Consolidate Net Profit

111.10

91.70

21.16%

Operating Profit Margin (Excl OI)

187.20%

180.00%

0.72%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 9.40% vs 2.83% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 21.16% vs 2.57% in Dec 2023

All Annual Results

Company CV

About Faes Farma SA

Faes Farma SA

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available